CymaBay Therapeutics Inc. (CBAY): Price and Financial Metrics


CymaBay Therapeutics Inc. (CBAY): $8.35

-0.20 (-2.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CBAY to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CBAY Stock Price Chart Interactive Chart >

Price chart for CBAY

CBAY Price/Volume Stats

Current price $8.35 52-week high $8.75
Prev. close $8.55 52-week low $1.67
Day low $8.23 Volume 1,263,800
Day high $8.60 Avg. volume 1,649,000
50-day MA $5.68 Dividend yield N/A
200-day MA $3.73 Market Cap 707.09M

CymaBay Therapeutics Inc. (CBAY) Company Bio


Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. The company was formerly known as Metabolex, Inc. The company was founded in 1988 and is based in Newark, California.


CBAY Latest News Stream


Event/Time News Detail
Loading, please wait...

CBAY Latest Social Stream


Loading social stream, please wait...

View Full CBAY Social Stream

Latest CBAY News From Around the Web

Below are the latest news stories about CYMABAY THERAPEUTICS INC that investors may wish to consider to help them evaluate CBAY as an investment opportunity.

CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference

NEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Securities Global Biopharma Conference. SVB Securities Global Biopharma ConferenceDate: Wednesday, February 15Time: 3:40 pm Eastern TimeLocation: VirtualFormat: Fireside ChatWebcast: http://ir.cymabay.com/events A

Yahoo | February 6, 2023

CymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEWARK, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need announced the closing, on January 26, 2023, of its previously announced underwritten public offering of its common stock and pre-funded warrants. CymaBay sold 11,821,428 shares of its common stock in the offering, including 1,821,428 shares pursuant to the full exer

Yahoo | January 30, 2023

CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

NEWARK, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants. CymaBay is selling 10,000,000 shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering.

Yahoo | January 24, 2023

CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

NEWARK, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by CymaBay. CymaBay intends to grant the underwriters a

Yahoo | January 23, 2023

Investors’ Faith in CymaBay Therapeutics Inc. (CBAY) could reap rewards if they hold on for the long haul

CymaBay Therapeutics Inc. (CBAY)’s stock is trading at $6.80 at the moment marking a rise of 4.38% from the last session close. As of this writing, shares are priced at 3.11% less than their 52-week high of $6.59, and 306.86% over their 52-week low of $1.67. Based on the past 30-day period, the stock price […]

US Post News | January 17, 2023

Read More 'CBAY' Stories Here

CBAY Price Returns

1-mo 41.29%
3-mo 159.32%
6-mo 123.26%
1-year 170.23%
3-year 438.71%
5-year -30.42%
YTD 33.17%
2022 85.50%
2021 -41.11%
2020 192.86%
2019 -75.10%
2018 -14.46%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7027 seconds.